Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer

Gene

Volumn 223, Issue 1-2, 1998, Pages 375-380

  Vogt, Ulf ^a   Bielawski, Krzysztof ^b,c   Schlotter, Claus M ^d   Bosse, Ulrich ^e   Falkiewicz, Bogdan ^b,f   Podhajska, Anna J ^b  

^a European Laboratory Association   (Germany)

^b Univ G   (Poland)

^c Hospital for Infectious Diseases   (Poland)

^d St Elisabeth Hospital   (Germany)

^e Institute of Pathology   (Germany)

^f UNIVERSITY OF GDA SK   (Poland)

Author keywords

Double differential PCR; Epidermal growth factor receptor family; Erb; Tyrosine kinase receptors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; ONCOPROTEIN; TYROSINE KINASE RECEPTOR;

ADULT; AGED; BREAST CANCER; CANCER CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC VALUE; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE NEU; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 0032570061     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1119(98)00454-5     Document Type: Conference Paper

References (30)

1. Bacus S.S., Chin D., Yarden Y., Zelnick C.R., Stern D.F. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am. J. Pathol. 148:1996;549-558.
2. Beerli R.R., Graus-Porta D., Woods-Cook K., Chen X., Yarden Y., Hynes N.E. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol. Cell. Biol. 15:1995;6496-6505.
3. Benz C.C., Brandt B.H., Zänker K.S. Gene diagnostics provide new insights into breast cancer prognosis and therapy. Gene. 159:1995;3-7.
4. Berns E.M.J.J., Foekens J.A., Van Staveren I.L., Van Putten W.L.J., De Koning H.Y.W.C.M., Portengen H., Klijn J.G.M. Oncogene amplification and prognosis in breast cancer relationship with systemic treatment. Gene. 159:1995;11-18.
5. Brandt B., Vogt U., Harms F., Bosse U., Zänker K.S., Assmann G. Double-differential PCR for gene dosage estimation of erbB oncogenes in benign and cancer tissues and comparison to cellular DNA content. Gene. 159:1995;29-34.
6. Brandt B., Vogt U., Schlotter C.M., Jackisch C., Werkmeister R., Thomas M., Von Eiff M., Bosse U., Assmann G., Zänker K.S. Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: double-differential polymerase chain reaction (ddPCR) for clinical diagnosis. Gene. 159:1995;35-42.
7. Carraway K.L., Carothers Carraway C.A., Carraway K.L. III Roles of ErbB-3 and ErbB-4 in the physiology and pathology of the mammary gland. J. Mammary Gland Biol. Neoplasia. 2:1997;187-198.
8. Chen X., Levkowitz G., Tzahar E., Karunagaran D., Lavi S., Ben-Baruch N., Leitner O., Ratzkin B.J., Bacus S.S., Yarden Y. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J. Biol. Chem. 271:1996;7620-7629.
9. Chen S.-Y., Yang A.-G., Chen J.-D., Kute T., King C.R., Collier J., Cong Y., Yao C., Huang X.F. Potent antitumour activity of a new class of tumour-specific killer cells. Nature. 385:1997;78-80.
10. Chow N.H., Liu H.S., Yang H.B., Chan S.H., Su I.J. Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. An immunohistochemical study. Virchows Arch. 430:1997;461-466.
11. Elenius K., Corfas G., Paul S., Choi C.J., Rio C., Plowman G.D., Klagsbrun M. A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J. Biol. Chem. 272:1997;26761-26768.
12. Fiddes R.J., Janes P.W., Sanderson G.M., Sivertsen S.P., Sutherland R.L., Daly R.J. Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells. Cell Growth Differ. 6:1995;1567-1577.
13. Gilbertson R.J., Perry R.H., Kelly P.J., Pearson A.D.J., Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res. 57:1997;3272-3280.
14. Grasso A.W., Wen D., Miller C.M., Rhim J.S., Pretlow T.G., Kung H.-J. ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene. 15:1997;2705-2716.
15. Han X., Kasahara N., Kan Y.W. Ligand-directed retroviral targeting of human breast cancer cells. Proc. Natl. Acad. Sci. USA. 92:1995;9747-9751.
16. Haugen D.R.F., Akslen L.A., Varhaug J.E., Lillehaug J.R. Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Res. 56:1996;1184-1188.
17. Higashiyama S., Horikawa M., Yamada K., Ichino N., Nakano N., Nakagawa T., Miyagawa J., Matsushita N., Nagatsu T., Taniguchi N., Ishiguro H. A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4. J. Biochem. (Tokyo). 122:1997;675-680.
18. Hung M.-C., Matin A., Zhang Y., Xing X., Sorgi F., Huang L., Yu D. HER-2/neu-targeting gene therapy - a review. Gene. 159:1995;65-71.
19. Hynes N.E. ErbB2 activation and signal transduction in normal and malignant mammary cells. J. Mammary Gland. Biol. Neoplasia. 1:1996;199-206.
20. Krane I.M., Leder P. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene. 12:1996;1781-1788.
21. Lyne J.C., Melhem M.F., Finley G.G., Wen D., Liu N., Deng D.H., Salup R. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J. Sci. Am. 3:1997;21-30.
22. Marengo S.R., Sikes R.A., Anezinis P., Chang S.M., Chung L.W. Metastasis induced by overexpression of p185neu-T after orthotopic injection into a prostatic epithelial cell line (NbE). Mol. Carcinogen. 19:1997;165-175.
23. erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA. 90:1993;1746-1750.
24. Ravdin P.M., Chamness G.C. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene. 159:1995;19-27.
25. Révillion F., Bonneterre J., Peyrat J.P. ERBB2 oncogene in human breast cancer and its clinical significance. Eur. J. Cancer. 34:1998;791-808.
26. Robinson D., He F., Pretlow T., Kung H.-J. A tyrosine kinase profile of prostate carcinoma. Proc. Natl. Acad. Sci. USA. 93:1996;5958-5962.
27. Spiessl, B., Beahrs, O.H., Hermanek, P., Hutter, R.V.P., Scheibe, O., Sobin, L.H., Wagner, G. 1990. TNM Atlas, 2nd ed. Springer, Heidelberg, pp. 173-180.
28. Wainstein M.A., He F., Robinson D., Kung H.-J., Schwartz S., Giaconia J.M., Edgehouse N.L., Pretlow T.P., Bodner D.R., Kursh E.D., Elroy D.K., Resnick M.I., Seftel A., Pretlow T.G. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res. 54:1994;6049-6052.
29. Wosikowski K., Schuurhuis D., Kops G.J.P.L., Saceda M., Bates S.E. Altered gene expression in drug-resistant human breast cancer cells. Clin. Cancer Res. 3:1997;2405-2414.
30. Zimonjic D.B., Alimandi M., Miki T., Popescu N.C., Kraus M.H. Localization of the human HER4/erbB-4 gene to chromosome 2. Oncogene. 10:1995;1235-1237.